var data={"title":"Pathogenesis of the hypercoagulable state associated with malignancy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of the hypercoagulable state associated with malignancy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/contributors\" class=\"contributor contributor_credentials\">Kenneth A Bauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/contributors\" class=\"contributor contributor_credentials\">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 23, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many patients with cancer are in a hypercoagulable state. The spectrum of manifestations ranges from abnormal coagulation tests in the absence of thrombotic symptoms to massive thromboembolism.</p><p>This topic review will discuss the pathogenetic factors that might contribute to the hypercoagulable syndromes that can be associated with malignancy [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/1\" class=\"abstract_t\">1</a>]. The contributions of chemotherapeutic drugs to the hypercoagulable state are discussed separately. (See <a href=\"topic.htm?path=drug-induced-thrombosis-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Drug-induced thrombosis in patients with malignancy&quot;</a>.)</p><p>The prevention and treatment of hypercoagulable disorders associated with malignancy are discussed separately. (See <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;</a> and <a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy#H455010\" class=\"medical medical_review\">&quot;Treatment of venous thromboembolism in patients with malignancy&quot;, section on 'Therapy in special populations'</a> and <a href=\"topic.htm?path=nonbacterial-thrombotic-endocarditis\" class=\"medical medical_review\">&quot;Nonbacterial thrombotic endocarditis&quot;</a> and <a href=\"topic.htm?path=drug-induced-thrombosis-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Drug-induced thrombosis in patients with malignancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of the hypercoagulable state of malignancy involves the interplay of multiple variables. As an example, intact tumor cells may express procoagulant activity that can directly induce thrombin generation; in addition, normal host tissues may express procoagulant activity in response to the tumor. Comorbid factors such as bed rest, infection, surgery, and drugs, may play a contributory role and may determine whether an asymptomatic increase in coagulability becomes manifest clinically [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/2,3\" class=\"abstract_t\">2,3</a>]. (See <a href=\"topic.htm?path=drug-induced-thrombosis-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Drug-induced thrombosis in patients with malignancy&quot;</a> and <a href=\"topic.htm?path=overview-of-the-causes-of-venous-thrombosis#H2\" class=\"medical medical_review\">&quot;Overview of the causes of venous thrombosis&quot;, section on 'Virchow's triad'</a> and <a href=\"topic.htm?path=overview-of-the-causes-of-venous-thrombosis#H24\" class=\"medical medical_review\">&quot;Overview of the causes of venous thrombosis&quot;, section on 'Malignancy'</a> and <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;</a>.)</p><p>Thrombotic episodes may precede the diagnosis of malignancy by months or years (see <a href=\"topic.htm?path=overview-of-the-causes-of-venous-thrombosis#H24\" class=\"medical medical_review\">&quot;Overview of the causes of venous thrombosis&quot;, section on 'Malignancy'</a>) and can present in one of the following ways [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Migratory superficial thrombophlebitis (Trousseau's syndrome)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic deep venous thrombosis and other sites of venous thrombosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonbacterial thrombotic endocarditis (marantic endocarditis)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disseminated intravascular coagulation (DIC)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arterial thrombosis</p><p/><p>Certain malignancies are more likely to be associated with venous thromboembolism (VTE) and other hypercoagulable disorders. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain solid tumors (eg, pancreatic cancer, brain tumors) are associated with a high incidence of VTE. Advanced tumor stage is also associated with greater risk of VTE. (See <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer#H5789100\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;, section on 'Incidence and risk factors'</a> and <a href=\"topic.htm?path=nonbacterial-thrombotic-endocarditis\" class=\"medical medical_review\">&quot;Nonbacterial thrombotic endocarditis&quot;</a> and <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;</a> and <a href=\"topic.htm?path=drug-induced-thrombosis-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Drug-induced thrombosis in patients with malignancy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myeloproliferative neoplasms are associated with VTE and microcirculatory disorders (eg, erythromelalgia). (See <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms#H2181747\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;, section on 'Thrombosis and bleeding'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H370300336\"><span class=\"h1\">MECHANISMS UNDERLYING THE HYPERCOAGULABLE STATE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early reports noted that many tumors associated with thrombotic complications were mucin-secreting adenocarcinomas of the gastrointestinal tract [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/5,6\" class=\"abstract_t\">5,6</a>]. However, many nonmucin-producing tumors are also associated with hypercoagulability and it has not been possible to purify a unique procoagulant moiety from mucin. The substances that have been isolated from animal and human tumors with procoagulant activity fall into two major categories: tissue factor-like procoagulant and cancer procoagulant [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer#H5789100\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;, section on 'Incidence and risk factors'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Tissue factor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tissue factor (TF) forms a complex with factor VII to activate factor IX and factor X, thereby initiating blood coagulation. TF is a transmembrane protein expressed by some normal human parenchymal and connective tissue cells and many malignant counterparts such as sarcoma, melanoma, neuroblastoma, lymphoma, pancreatic and colorectal cancer, ovarian cancer (especially the clear cell variant), and acute promyelocytic leukemia (APL) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/8-17\" class=\"abstract_t\">8-17</a>]. Tissue factor expression may correlate inversely with the degree of differentiation of the tumor [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/18,19\" class=\"abstract_t\">18,19</a>]. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H87005698\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Chronic DIC'</a>.)</p><p>However, data indicating the importance of TF expressed on tumor cells as a procoagulant should be interpreted with caution, since the expression of TF antigen and activity depends heavily upon the source of malignant tissue [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/20\" class=\"abstract_t\">20</a>]. As an example, TF expression is frequently studied in cell culture, a milieu that may not be representative of that found in vivo [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/16,21\" class=\"abstract_t\">16,21</a>].</p><p>Tissue factor has been implicated in the hypercoagulable state associated with APL and, less often, other subtypes of acute myeloid leukemia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/8,22-24\" class=\"abstract_t\">8,22-24</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-promyelocytic-leukemia-in-adults#H5\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults&quot;, section on 'Coagulopathy and APL'</a>.)</p><p>Myeloid precursor cells from normal bone marrow do not possess procoagulant activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/25\" class=\"abstract_t\">25</a>]. The induction of leukemia cell differentiation with all-trans-retinoic acid downregulates the expression of TF, cancer procoagulant, and annexin II and improves the hypercoagulable state [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/26-29\" class=\"abstract_t\">26-29</a>]. In one series, for example, plasma fibrinogen began to increase and D-dimer and thrombin-antithrombin complex levels began to fall within two to four days after the onset of all-trans-retinoic acid therapy; the values were normal or near normal by eight days [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Tissue factor-bearing microparticles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tissue factor antigen is present in plasma [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/30\" class=\"abstract_t\">30</a>]. Some of the molecules are truncated, or result from alternative splicing of TF mRNA, and lack the transmembrane domain [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/31\" class=\"abstract_t\">31</a>]. There is considerable interest in assessing the physiologic importance of such blood-borne TF in microparticles [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/32-36\" class=\"abstract_t\">32-36</a>], as well as their potential role in the pathogenesis of the hypercoagulable state accompanying cancer, sepsis, and sickle cell disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/37-39\" class=\"abstract_t\">37-39</a>].</p><p>Using impedance-based flow cytometry, tissue factor-bearing microparticles (TFMP) were studied in patients with malignancy, leading to the following salient observations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/40\" class=\"abstract_t\">40</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TFMP were detected in patients with advanced malignancy, including two-thirds of patients with pancreatic carcinoma.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated levels of TFMP were associated with VTE in a cohort of 96 cancer patients of different histologies (adjusted OR 3.72; 95% CI 1.18-11.8).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a group of 60 cancer patients without VTE, a retrospective analysis revealed a cumulative incidence of VTE of 34.8 versus zero percent at one year in those with (4 of 16) or without (zero of 44) TFMP, respectively.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pancreatectomy with curative intent in three patients eliminated or nearly eliminated these microparticles. Microparticles in these patients coexpressed the epithelial tumor antigen MUC-1 found on pancreatic tumor cells, providing evidence that they were derived from the tumor cells rather than from platelets or other cells of hematologic origin.</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Cancer procoagulant</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cancer procoagulant (CP) is a calcium-dependent cysteine protease that has been found in malignant and fetal tissue, but not normally differentiated tissue [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/41-43\" class=\"abstract_t\">41-43</a>]. It activates factor X directly, independent of the tissue <span class=\"nowrap\">factor/factor</span> VIIa complex [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/44\" class=\"abstract_t\">44</a>]. Cancer procoagulant has been reported to be present in extracts of cells obtained from patients with acute promyelocytic leukemia, malignant melanoma, and cancers of the colon, breast, lung, and kidney [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/8,45,46\" class=\"abstract_t\">8,45,46</a>].</p><p>To date, only a small amount of sequence has been obtained and the cDNA of this procoagulant has not been cloned. CP is not currently felt to be important in the pathogenesis of the hypercoagulable state associated with malignancy.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Procoagulant activities expressed by host tissues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Normal cells can be stimulated to express procoagulant activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/47\" class=\"abstract_t\">47</a>]. In patients harboring a malignancy, these normal cells can play an important role in activating the hemostatic mechanism and ultimately in fibrin deposition.</p><p>Among these activators is the cell adhesion molecule P-selectin, found in the alpha granules of platelets and the Weibel-Palade bodies of endothelial cells. Among other functions, P-selectin increases the expression of tissue factor on monocytes and endothelial cells.</p><p>High plasma levels of P-selectin are prothrombotic in experimental animals [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/48\" class=\"abstract_t\">48</a>], and have been associated with an increased risk of VTE in cancer patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=leukocyte-endothelial-adhesion-in-the-pathogenesis-of-inflammation#H4\" class=\"medical medical_review\">&quot;Leukocyte-endothelial adhesion in the pathogenesis of inflammation&quot;, section on 'Selectins'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Monocytes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Monocytes constitutively express little if any procoagulant activity (PCA). However, they can be induced to produce tissue factor and other direct factor X activators [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/50\" class=\"abstract_t\">50</a>] by T lymphocytes, antigens, cytokines, lipoproteins, immune complexes, endotoxin and complement [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/51-55\" class=\"abstract_t\">51-55</a>].</p><p>Monocytes may also become activated by tumor-specific antigens, immune complexes involving tumor antigens, or indirectly by cytokines secreted by other immune cells in response to tumor related antigens. In a study of patients with lung cancer, for example, pulmonary alveolar macrophages close to the tumor expressed increased tissue factor activity in vitro compared with cells from normal controls or macrophages from the contralateral side of the neoplasm [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/56\" class=\"abstract_t\">56</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Platelets</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased platelet reactivity secondary to either clonal abnormalities (eg, myeloproliferative disorders) or tumor-platelet interactions could contribute to hypercoagulability. Substances have been obtained from various animal and human tumors that can directly aggregate platelets [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/57,58\" class=\"abstract_t\">57,58</a>]. However, efforts to recover and purify the active species from detergent-solubilized tumor cell membranes have thus far been unsuccessful.</p><p>Other mechanisms proposed for increased platelet activation in malignancy include tumor-induced thrombin generation, ADP production by tumor cells, and elevated levels of von Willebrand factor (vWF) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/59-61\" class=\"abstract_t\">59-61</a>]. It is postulated that platelet proaggregatory moieties may lead to clot formation on the vascular subendothelium, thereby stimulating hemostatic activation.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Endothelial cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endothelial cells may become procoagulant under the influence of inflammatory cytokines and other peptide products. In particular, both tumor necrosis factor (TNF) and interleukin (IL)-1 increase the expression of leukocyte adhesion molecules, platelet activating factor, and tissue factor. TNF also suppresses endothelial fibrinolytic activity, increases endothelial cell production of IL-1, and downregulates thrombomodulin expression, which diminishes the activation of the anticoagulant protein C.</p><p>By virtue of these effects, TNF is able to dramatically enhance the procoagulant and suppress the anticoagulant properties of cultured vascular endothelial cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/62,63\" class=\"abstract_t\">62,63</a>]. In one study, infusion of TNF into patients with cancer produced a substantial net procoagulant stimulus to the hemostatic system [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/64\" class=\"abstract_t\">64</a>].</p><p>Whether or not TNF levels are significantly and consistently elevated in patients with malignancy has not been determined. In one series, increased serum TNF concentrations were noted in as many as 50 percent of cancer patients with active disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/65\" class=\"abstract_t\">65</a>]. However, other reports have only infrequently observed elevated serum TNF in such patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/66,67\" class=\"abstract_t\">66,67</a>].</p><p>Endothelial damage is thought to underlie hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease of the liver). (See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation#H8038149\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;, section on 'Pathogenesis'</a>.)</p><p class=\"headingAnchor\" id=\"H1638223878\"><span class=\"h3\">Neutrophils</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dying neutrophils can produce web-like structures known as neutrophil extracellular traps (NETs), which are composed of decondensed chromatin coated with a variety of cellular proteins. NETs may be produced in the setting of a number of infectious and inflammatory conditions, and they have been proposed to play a role in the formation of thrombi, including those associated with certain malignancies. Mechanisms are discussed in more detail separately. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H2877027455\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Role of extracellular cell-free DNA and DNA-binding proteins'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">TUMOR-SPECIFIC MECHANISMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following tumor-specific mechanisms may also occur:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Polyphosphate</strong> &ndash; Polyphosphates provide a negatively charged surface that triggers the intrinsic pathway of coagulation (see <a href=\"topic.htm?path=overview-of-hemostasis#H349234200\" class=\"medical medical_review\">&quot;Overview of hemostasis&quot;, section on 'Critical role of polyphosphate in initiating blood clotting via the intrinsic contact pathway'</a>). A study using plasma samples from patients with prostate cancer identified small vesicles (prostasomes) rich in polyphosphate that could promote thrombin generation via activation of coagulation factor XII [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/68\" class=\"abstract_t\">68</a>]. Abundance of these vesicles correlated with a clinical history of thrombosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>MET oncogene</strong> &ndash; MET is a tyrosine kinase receptor for hepatocyte growth factor that is expressed in a number of tumor types. A hypercoagulable syndrome was mimicked in an animal model by targeting the activated human MET oncogene to the murine liver, promoting carcinogenesis in the liver [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/69\" class=\"abstract_t\">69</a>]. This was preceded and accompanied by venous thromboses, evolving towards fatal internal hemorrhages. The syndrome was apparently driven by the transcriptional response to the MET oncogene, including upregulation of the plasminogen activator inhibitor type 1 and cyclooxygenase-2 genes. (See <a href=\"topic.htm?path=thrombotic-and-hemorrhagic-disorders-due-to-abnormal-fibrinolysis#H19\" class=\"medical medical_review\">&quot;Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis&quot;, section on 'Plasminogen activator inhibitor'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">PATIENT COMORBIDITIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of clinical factors may contribute to the thrombotic tendency in cancer patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/70\" class=\"abstract_t\">70</a>]. These include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vascular stasis due to obstruction of blood flow by the tumor or patient immobility (ie, bedrest, hospitalization)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sepsis <span class=\"nowrap\">and/or</span> disseminated intravascular coagulation (see <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Advanced age (see <a href=\"topic.htm?path=normal-aging#H23810861\" class=\"medical medical_review\">&quot;Normal aging&quot;, section on 'Hematopoietic system'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombocytosis <span class=\"nowrap\">and/or</span> leukocytosis (see <a href=\"topic.htm?path=approach-to-the-patient-with-thrombocytosis\" class=\"medical medical_review\">&quot;Approach to the patient with thrombocytosis&quot;</a> and <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer#H1339405\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;, section on 'VTE risk assessment/Khorana score'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain antineoplastic agents (see <a href=\"topic.htm?path=drug-induced-thrombosis-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Drug-induced thrombosis in patients with malignancy&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythropoiesis stimulating agents (see <a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer#H264001313\" class=\"medical medical_review\">&quot;Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer&quot;, section on 'Thromboembolic risk'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indwelling central venous catheters used for administration of chemotherapy (see <a href=\"topic.htm?path=catheter-related-upper-extremity-venous-thrombosis\" class=\"medical medical_review\">&quot;Catheter-related upper extremity venous thrombosis&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H781183754\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain malignancies and advanced malignancies are associated with increased risk of thromboembolic disease. (See <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer#H5789100\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;, section on 'Incidence and risk factors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The spectrum of hypercoagulable <span class=\"nowrap\">and/or</span> thrombotic manifestations in cancer patients ranges from abnormal coagulation tests in the absence of thrombotic symptoms to massive thromboembolism. These are discussed in separate topic reviews:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Migratory superficial thrombophlebitis (Trousseau's syndrome) &ndash; (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults#H87005698\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;, section on 'Chronic DIC'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Idiopathic deep venous thrombosis and other sites of venous thrombosis &ndash; (See <a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Treatment of venous thromboembolism in patients with malignancy&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Nonbacterial thrombotic endocarditis (marantic endocarditis) &ndash; (See <a href=\"topic.htm?path=nonbacterial-thrombotic-endocarditis\" class=\"medical medical_review\">&quot;Nonbacterial thrombotic endocarditis&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Disseminated intravascular coagulation (DIC) &ndash; (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura [TTP], drug-induced thrombotic microangiopathy [DITMA]) &ndash; (See <a href=\"topic.htm?path=acquired-ttp-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Acquired TTP: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Arterial thrombosis &ndash; (See <a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy#H455010\" class=\"medical medical_review\">&quot;Treatment of venous thromboembolism in patients with malignancy&quot;, section on 'Therapy in special populations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenesis of the hypercoagulable state of malignancy involves the interplay of multiple variables, including the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Tissue factor is a transmembrane protein expressed by some normal human parenchymal and connective tissue cells and many malignant counterparts such as sarcoma, melanoma, neuroblastoma, lymphoma, pancreatic and colorectal cancer, ovarian cancer (especially the clear cell variant), and acute promyelocytic leukemia. (See <a href=\"#H3\" class=\"local\">'Tissue factor'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A number of normal host tissues can be stimulated to express procoagulant activity. These include platelets, endothelial cells, and monocytes. (See <a href=\"#H6\" class=\"local\">'Procoagulant activities expressed by host tissues'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A number of clinical factors may contribute to the thrombotic tendency in cancer patients. These include vascular stasis, hepatic involvement and dysfunction, sepsis <span class=\"nowrap\">and/or</span> disseminated intravascular coagulation, advanced age, thrombocytosis <span class=\"nowrap\">and/or</span> leukocytosis, certain antineoplastic agents, erythropoiesis stimulating agents, and indwelling central venous catheters. (See <a href=\"#H12\" class=\"local\">'Patient comorbidities'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/1\" class=\"nounderline abstract_t\">Dipasco PJ, Misra S, Koniaris LG, Moffat FL Jr. Thrombophilic state in cancer, part I: biology, incidence, and risk factors. J Surg Oncol 2011; 104:316.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/2\" class=\"nounderline abstract_t\">Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6:401.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/3\" class=\"nounderline abstract_t\">Young A, Chapman O, Connor C, et al. Thrombosis and cancer. Nat Rev Clin Oncol 2012; 9:437.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/4\" class=\"nounderline abstract_t\">Levine M. Treatment of thrombotic disorders in cancer patients. Haemostasis 1997; 27 Suppl 1:38.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/5\" class=\"nounderline abstract_t\">Amico L, Caplan LR, Thomas C. Cerebrovascular complications of mucinous cancers. Neurology 1989; 39:522.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/6\" class=\"nounderline abstract_t\">Pinzon R, Drewinko B, Trujillo JM, et al. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center. J Clin Oncol 1986; 4:509.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/7\" class=\"nounderline abstract_t\">Edwards RL, Morgan DL, Rickles FR. Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost 1990; 63:133.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/8\" class=\"nounderline abstract_t\">Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/9\" class=\"nounderline abstract_t\">Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/10\" class=\"nounderline abstract_t\">Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11:249.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/11\" class=\"nounderline abstract_t\">Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/12\" class=\"nounderline abstract_t\">Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/13\" class=\"nounderline abstract_t\">Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96:290.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/14\" class=\"nounderline abstract_t\">Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6:1983.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/15\" class=\"nounderline abstract_t\">Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/16\" class=\"nounderline abstract_t\">Yokota N, Koizume S, Miyagi E, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer 2009; 101:2023.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/17\" class=\"nounderline abstract_t\">Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk 2014; 14:441.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/18\" class=\"nounderline abstract_t\">Kakkar AK, Lemoine NR, Scully MF, et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82:1101.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/19\" class=\"nounderline abstract_t\">Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77:1877.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/20\" class=\"nounderline abstract_t\">Zucchella M, Pacchiarini L, Tacconi F, et al. Different expression of procoagulant activity in human cancer cells cultured &quot;in vitro&quot; or in cells isolated from human tumor tissues. Thromb Haemost 1993; 69:335.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/21\" class=\"nounderline abstract_t\">Curatolo L, Alessio MG, Casali B, et al. Procoagulant activity of mouse transformed cells: different expression in freshly isolated or cultured cells. In Vitro Cell Dev Biol 1988; 24:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/22\" class=\"nounderline abstract_t\">Koyama T, Hirosawa S, Kawamata N, et al. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994; 84:3001.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/23\" class=\"nounderline abstract_t\">Guarini A, Gugliotta L, Timoncini C, et al. Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scand J Haematol 1985; 34:152.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/24\" class=\"nounderline abstract_t\">Wada H, Nagano T, Tomeoku M, et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1983; 30:315.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/25\" class=\"nounderline abstract_t\">Guarini A, Gugliotta L, Valvassori L, et al. Human myeloid precursor cells do not possess or produce procoagulant activity (PCA). Exp Hematol 1986; 14:72.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/26\" class=\"nounderline abstract_t\">Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92:143.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/27\" class=\"nounderline abstract_t\">Saito T, Koyama T, Nagata K, et al. Anticoagulant effects of retinoic acids on leukemia cells. Blood 1996; 87:657.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/28\" class=\"nounderline abstract_t\">Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995; 86:1072.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/29\" class=\"nounderline abstract_t\">Arbuthnot C, Wilde JT. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev 2006; 20:289.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/30\" class=\"nounderline abstract_t\">Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96:2311.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/31\" class=\"nounderline abstract_t\">Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/32\" class=\"nounderline abstract_t\">Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197:1585.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/33\" class=\"nounderline abstract_t\">Chou J, Mackman N, Merrill-Skoloff G, et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104:3190.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/34\" class=\"nounderline abstract_t\">Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105:192.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/35\" class=\"nounderline abstract_t\">Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5:520.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/36\" class=\"nounderline abstract_t\">Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119:5543.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/37\" class=\"nounderline abstract_t\">Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97:119.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/38\" class=\"nounderline abstract_t\">Tesselaar ME, Romijn FP, van der Linden IK, et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7:1421.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/39\" class=\"nounderline abstract_t\">Zahra S, Anderson JA, Stirling D, Ludlam CA. Microparticles, malignancy and thrombosis. Br J Haematol 2011; 152:688.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/40\" class=\"nounderline abstract_t\">Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15:6830.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/41\" class=\"nounderline abstract_t\">Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981; 67:1665.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/42\" class=\"nounderline abstract_t\">Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24:5558.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/43\" class=\"nounderline abstract_t\">Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8:73.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/44\" class=\"nounderline abstract_t\">Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6:127.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/45\" class=\"nounderline abstract_t\">Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/46\" class=\"nounderline abstract_t\">Donati MB, Gambacorti-Passerini C, Casali B, et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46:6471.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/47\" class=\"nounderline abstract_t\">Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78:759.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/48\" class=\"nounderline abstract_t\">Andr&eacute; P, Hartwell D, Hrachovinov&aacute; I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 2000; 97:13835.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/49\" class=\"nounderline abstract_t\">Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/50\" class=\"nounderline abstract_t\">Altieri DC, Edgington TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988; 263:7007.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/51\" class=\"nounderline abstract_t\">Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Semin Hematol 1992; 29:202.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/52\" class=\"nounderline abstract_t\">Edwards RL, Rickles FR, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54:359.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/53\" class=\"nounderline abstract_t\">Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72:128.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/54\" class=\"nounderline abstract_t\">Gregory SA, Kornbluth RS, Helin H, et al. Monocyte procoagulant inducing factor: a lymphokine involved in the T cell-instructed monocyte procoagulant response to antigen. J Immunol 1986; 137:3231.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/55\" class=\"nounderline abstract_t\">Levy GA, Schwartz BS, Curtiss LK, Edgington TS. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. J Clin Invest 1981; 67:1614.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/56\" class=\"nounderline abstract_t\">Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med 1981; 98:917.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/57\" class=\"nounderline abstract_t\">Hara Y, Steiner M, Baldini MG. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res 1980; 40:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/58\" class=\"nounderline abstract_t\">Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci U S A 1980; 77:4336.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/59\" class=\"nounderline abstract_t\">Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990; 59:955.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/60\" class=\"nounderline abstract_t\">Sweeney JD, Killion KM, Pruet CF, Spaulding MB. von Willebrand factor in head and neck cancer. Cancer 1990; 66:2387.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/61\" class=\"nounderline abstract_t\">Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3:425.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/62\" class=\"nounderline abstract_t\">Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83:4533.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/63\" class=\"nounderline abstract_t\">Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/64\" class=\"nounderline abstract_t\">Bauer KA, ten Cate H, Barzegar S, et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74:165.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/65\" class=\"nounderline abstract_t\">Balkwill F, Osborne R, Burke F, et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; 2:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/66\" class=\"nounderline abstract_t\">Scuderi P, Sterling KE, Lam KS, et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986; 2:1364.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/67\" class=\"nounderline abstract_t\">Waage A, Espevik T, Lamvik J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986; 24:739.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/68\" class=\"nounderline abstract_t\">Nickel KF, Ronquist G, Langer F, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/69\" class=\"nounderline abstract_t\">Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434:396.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-the-hypercoagulable-state-associated-with-malignancy/abstract/70\" class=\"nounderline abstract_t\">Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11:223.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1353 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H781183754\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">OVERVIEW</a></li><li><a href=\"#H370300336\" id=\"outline-link-H370300336\">MECHANISMS UNDERLYING THE HYPERCOAGULABLE STATE</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Tissue factor</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Tissue factor-bearing microparticles</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Cancer procoagulant</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Procoagulant activities expressed by host tissues</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Monocytes</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Platelets</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Endothelial cells</a></li><li><a href=\"#H1638223878\" id=\"outline-link-H1638223878\">- Neutrophils</a></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">TUMOR-SPECIFIC MECHANISMS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">PATIENT COMORBIDITIES</a></li><li><a href=\"#H781183754\" id=\"outline-link-H781183754\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-ttp-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Acquired TTP: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-thrombocytosis\" class=\"medical medical_review\">Approach to the patient with thrombocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=catheter-related-upper-extremity-venous-thrombosis\" class=\"medical medical_review\">Catheter-related upper extremity venous thrombosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-in-adults\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombosis-in-patients-with-malignancy\" class=\"medical medical_review\">Drug-induced thrombosis in patients with malignancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">Drug-induced thrombotic microangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=leukocyte-endothelial-adhesion-in-the-pathogenesis-of-inflammation\" class=\"medical medical_review\">Leukocyte-endothelial adhesion in the pathogenesis of inflammation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nonbacterial-thrombotic-endocarditis\" class=\"medical medical_review\">Nonbacterial thrombotic endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=normal-aging\" class=\"medical medical_review\">Normal aging</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">Overview of hemostasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-causes-of-venous-thrombosis\" class=\"medical medical_review\">Overview of the causes of venous thrombosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">Overview of the myeloproliferative neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">Risk and prevention of venous thromboembolism in adults with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-patients-with-cancer\" class=\"medical medical_review\">Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thrombotic-and-hemorrhagic-disorders-due-to-abnormal-fibrinolysis\" class=\"medical medical_review\">Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy\" class=\"medical medical_review\">Treatment of venous thromboembolism in patients with malignancy</a></li></ul></div></div>","javascript":null}